EFTR (eFFECTOR Therapeutics) Interest Expense : $-2.98 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is eFFECTOR Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. eFFECTOR Therapeutics's interest expense for the three months ended in Mar. 2024 was $ -0.75 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.98 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. eFFECTOR Therapeutics's Operating Income for the three months ended in Mar. 2024 was $ -8.40 Mil. eFFECTOR Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $ -0.75 Mil. eFFECTOR Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

eFFECTOR Therapeutics Interest Expense Historical Data

The historical data trend for eFFECTOR Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

eFFECTOR Therapeutics Interest Expense Chart

eFFECTOR Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Interest Expense

-1.33

-1.76

-2.25

-2.92

eFFECTOR Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial										-0.69	-0.72	-0.75	-0.76	-0.75

eFFECTOR Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.98 Mil.

eFFECTOR Therapeutics (OTCPK:EFTR) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

eFFECTOR Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $-0.75 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-8.40 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.18 Mil.

eFFECTOR Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

eFFECTOR Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

eFFECTOR Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » eFFECTOR Therapeutics Inc (OTCPK:EFTR) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

142 North Cedros Avenue, Suite B, Solana Beach, CA, USA, 92075

Website

https://www.effector.com

eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).

Executives

Sr One Capital Fund I Aggregator Lp	10 percent owner	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Christopher B Ehrlich	director, 10 percent owner, officer: Chief Executive Officer	499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Mayank Gandhi	officer: Chief Business Officer	628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Douglas J Warner	officer: Chief Medical Officer	C/O EFFECTOR THERAPEUTICS, INC., 142 NORTH CEDROS AVENUE, SUITE B, SOLANA BEACH CA 92075
Presidio Management Group X Llc	10 percent owner	2735 SAND HILL ROAD, MENLO PARK CA 94025
Carlyle Group Inc.	10 percent owner	C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Carlyle Genesis Uk Llc	10 percent owner	C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004
Carlyle Investment Management Llc	10 percent owner	1001 PENNSYLVANIA AVE. N.W., WASHINGTON DC 20004
Carlyle Holdings I L.p.	10 percent owner	C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Carlyle Holdings I Gp Inc.	10 percent owner	C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Tc Group, Llc	10 percent owner	C/O CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE NW SUITE 220 S, WASHINGTON DC 20004
Cg Subsidiary Holdings L.l.c.	10 percent owner	C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Carlyle Holdings I Gp Sub L.l.c.	10 percent owner	C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Gallagher Brian M. Jr.	director, 10 percent owner	C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139
Stephen T Worland	director, officer: President and Chief Executive	9050 CAMINO SANTA FE, SAN DIEGO CA 92121